Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 18;193(3):548-552.
doi: 10.1093/bjd/ljaf166.

Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis

Affiliations

Living network meta-analysis to compare nemolizumab against other available targeted systemic treatments for atopic dermatitis

Aaron M Drucker et al. Br J Dermatol. .

Abstract

Nemolizumab is a new biologic approved to treat atopic dermatitis. In this perspective piece, we use results from our living systematic review and network meta-analysis to provide perspective on the relative efficacy of nemolizumab compared with other approved targeted systemic treatments.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: The full Conflicts of Interest statement can be found in Appendix S2 (see Supporting Information).

Figures

Figure 1
Figure 1
Forest plots of network meta-analysis results of adultsa treated between 8 and 16 weeks for change in (a) Eczema Area and Severity Index (EASI), (b) Patient-Oriented Eczema Measure (POEM), (c) Dermatology Life Quality Index (DLQI) and (d) Peak Pruritus Numeric Rating Scale (PP-NRS). Results are presented as mean difference (MD) with 95% credible intervals (CrI) for selected currently available targeted medications vs. dupilumab 600 mg then 300 mg every 2 weeks. MDs > 0 indicate that the comparator is associated with more improvement than dupilumab. MDs < 0 indicate that the comparator is associated with less improvement than dupilumab. Results for the complete networks are available on request. Abrocitinib 100, abrocitinib 100 mg daily; Abrocitinib 200, abrocitinib 200 mg daily; Baricitinib 2, baricitinib 2 mg daily; Baricitinib 4, baricitinib 4 mg daily; Lebrikizumab, lebrikizumab 500 mg at weeks 0 and 2 then 250 mg every 2 weeks; Nemolizumab, nemolizumab 60 mg then 30 mg every 4 weeks; Tralokinumab, tralokinumab 600 mg then 300 mg every 2 weeks; Upadacitinib 15, upadacitinib 15 mg daily; Upadacitinib 30, upadacitinib 30 mg daily. aSome studies included in the analyses of trials of adults include a minority proportion of adolescent participants (12–17 years old).
Figure 1
Figure 1
Forest plots of network meta-analysis results of adultsa treated between 8 and 16 weeks for change in (a) Eczema Area and Severity Index (EASI), (b) Patient-Oriented Eczema Measure (POEM), (c) Dermatology Life Quality Index (DLQI) and (d) Peak Pruritus Numeric Rating Scale (PP-NRS). Results are presented as mean difference (MD) with 95% credible intervals (CrI) for selected currently available targeted medications vs. dupilumab 600 mg then 300 mg every 2 weeks. MDs > 0 indicate that the comparator is associated with more improvement than dupilumab. MDs < 0 indicate that the comparator is associated with less improvement than dupilumab. Results for the complete networks are available on request. Abrocitinib 100, abrocitinib 100 mg daily; Abrocitinib 200, abrocitinib 200 mg daily; Baricitinib 2, baricitinib 2 mg daily; Baricitinib 4, baricitinib 4 mg daily; Lebrikizumab, lebrikizumab 500 mg at weeks 0 and 2 then 250 mg every 2 weeks; Nemolizumab, nemolizumab 60 mg then 30 mg every 4 weeks; Tralokinumab, tralokinumab 600 mg then 300 mg every 2 weeks; Upadacitinib 15, upadacitinib 15 mg daily; Upadacitinib 30, upadacitinib 30 mg daily. aSome studies included in the analyses of trials of adults include a minority proportion of adolescent participants (12–17 years old).

References

    1. Silverberg JI, Wollenberg A, Reich A et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet 2024; 404:445–60. - PubMed
    1. Drucker AM, Ellis A, Jabbar-Lopez Z et al. Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. BMJ Open 2018; 8:e023061. - PMC - PubMed
    1. Drucker AM, Ellis AG, Bohdanowicz M et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis. JAMA Dermatol 2020; 156:659–67. - PMC - PubMed
    1. Drucker AM, Morra DE, Prieto-Merino D et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis. JAMA Dermatol 2022; 158:523–32. - PMC - PubMed
    1. Drucker AM, Lam M, Elsawi R et al. Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis. Br J Dermatol 2024; 190:184–90. - PubMed